| Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
|
(Nektar Therapeutics)
|
02-Jun-2008 |
| New Positive Data Announced for NKTR-102 (PEG-irinotecan), Highlights Promise of Nektar's Innovative Small Molecule PEG-Oncolytics
|
(Nektar Therapeutics)
|
02-Jun-2008 |
| Newly-Approved Cimzia® Provides Rapid, Sustained Response in Crohn’s Patients
|
(UCB)
|
20-May-2008 |
| Cimzia® Provides Long-Term Efficacy With Stable Dosing in Crohn’s Disease
|
(UCB)
|
20-May-2008 |
| Amikacin Inhale Shows Promising Results in Phase II Study
|
(Nektar Therapeutics)
|
19-May-2008 |
| Amikacin Inhale Shows Promising Results in Phase II Study
|
(Bayer AG)
|
19-May-2008 |
| PEGASYS®/COPEGUS® Show Benefit in Hard-to-Treat Latino Population with Hepatitis C
|
(Roche)
|
18-May-2008 |
| Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
|
(Nektar Therapeutics)
|
16-May-2008 |
| Lantheus Medical Imaging Updates DEFINITY® Label to Modify Benefit/risk Assessment of the Product
|
(Lantheus Medical Imaging)
|
13-May-2008 |
| Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
|
(Nektar Therapeutics)
|
12-May-2008 |
| Affymax and Takeda Announce Long-Term Hematide Safety and Effectiveness Data from Phase 2 Clinical Trials in Chronic Kidney Disease Patients with Anemia
|
(Affymax)
|
12-May-2008 |
| MIRCERA Keeps Haemoglobin Levels Stable With Significantly Fewer Dose Changes Than With Other ESAs
|
(Roche)
|
12-May-2008 |
| NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
|
(Nektar Therapeutics)
|
07-May-2008 |
| Lantheus Medical Imaging Initiates Cares Registry to Further Evaluate Definity® in Patients With Suboptimal Echocardiograms
|
(Lantheus Medical Imaging)
|
06-May-2008 |
| Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C
|
(Roche)
|
28-Apr-2008 |
| Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
|
(Schering-Plough)
|
26-Apr-2008 |
| FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform
|
(Nektar Therapeutics)
|
23-Apr-2008 |
| Cimzia(R), Utilizing Enzon's Pegylation Technology, Approved in the U.S.
|
(Enzon Pharmaceuticals)
|
23-Apr-2008 |
| Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
|
(Schering-Plough)
|
17-Apr-2008 |
| Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
|
(Nektar Therapeutics)
|
14-Apr-2008 |
| Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin
|
(Nektar Therapeutics)
|
09-Apr-2008 |
| Pfizer Statement on Exubera Labeling Update in the United States
|
(Pfizer)
|
09-Apr-2008 |
| Affymax and Takeda Report Long-Term Safety and Effectiveness Data of Hematide in Chronic Renal Failure Patients With Anemia
|
(Affymax)
|
04-Apr-2008 |
| Phase II Results for CDP791 in Non-Small Cell Lung Cancer Support Further Clinical Development
|
(UCB)
|
31-Mar-2008 |
| PEGINTRON(TM) Plus Weight-Based REBETOL(R) Resulted in Higher SVR Than Flat Dosing
|
(Schering-Plough)
|
27-Mar-2008 |
| CHMP Upholds Negative Opinion for the EU Application for Cimzia® in the Treatment of Crohn’s Disease
|
(UCB)
|
20-Mar-2008 |
| MannKind - last gasp for inhaled insulin
|
(Alkermes)
|
10-Mar-2008 |
| MIRCERA® Successfully Corrects Anaemia With a Smooth and Steady Rise in Haemoglobin Levels in Line With Current Guidelines
|
(Roche)
|
05-Mar-2008 |
| Early Data on Cimzia® from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn’s Disease Patients
|
(UCB)
|
04-Mar-2008 |
| FDA Agrees to Review Cimzia® File for the Treatment of Rheumatoid Arthritis
|
(UCB)
|
06-Feb-2008 |
| FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
|
(Schering-Plough)
|
31-Jan-2008 |
| Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide™ to Treat Chemotherapy Induced Anemia
|
(Takeda)
|
25-Jan-2008 |
| Takeda Doses First Patient in A U.S. Phase 1 Study of Hematide™ to Treat Chemotherapy Induced Anemia
|
(Affymax)
|
25-Jan-2008 |
| Inhaled insulin running out of puff?
|
(Novo Nordisk)
|
15-Jan-2008 |
| Schering-Plough Reports Top-Line Results of the IDEAL Study
|
(Schering-Plough)
|
14-Jan-2008 |
| Roche Responds to Announcement of “IDEAL” Hepatitis C Trial Results
|
(Roche)
|
14-Jan-2008 |
| Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
|
(Nektar Therapeutics)
|
08-Jan-2008 |
| Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
|
(Nektar Therapeutics)
|
08-Jan-2008 |
| Baxter Announces Recombinant Factor IX Development Program for Hemophilia B
|
(Baxter International)
|
07-Jan-2008 |
| Nektar, still reeling from Exubera, now faces Cimzia fallout
|
(UCB)
|
16-Nov-2007 |
| Nektar's Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
|
(Nektar Therapeutics)
|
14-Nov-2007 |
| FDA Approves MIRCERA®: First Renal Anemia Treatment with Monthly Maintenance Dosing
|
(Roche)
|
14-Nov-2007 |
| MIRCERA® Shown to be Effective Anaemia Treatment for Renal Patients With Low Haemoglobin Levels
|
(Roche)
|
05-Nov-2007 |
| Treatment with Pegasys Provides Hepatitis C Patients a Second Chance to Achieve a Cure After not Responding to Peg-intron
|
(Roche)
|
02-Nov-2007 |
| Treatment with PEGASYS®/COPEGUS™ Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron®/Ribavirin
|
(Roche)
|
02-Nov-2007 |
| NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
|
(Nektar Therapeutics)
|
25-Oct-2007 |
| Pivotal Mircera Study First to Convert Dialysis Patients from Frequent Dosing Directly to Once Every Four Weeks
|
(Roche)
|
19-Oct-2007 |
| New MIRCERA® Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
|
(Roche)
|
17-Oct-2007 |
| Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors to be Presented at Upcoming AACR-NCI-EORTC International Conference
|
(Nektar Therapeutics)
|
10-Oct-2007 |
| NKTR-102 (PEG-Irinotecan) Demonstrates Significant Anti-Tumor Activity and Improved Pharmacokinetic Profile in Preclinical Studies Presented at ECCO
|
(Nektar Therapeutics)
|
27-Sep-2007 |
| Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
|
(Nektar Therapeutics)
|
26-Sep-2007 |
| New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
|
(Pfizer)
|
18-Sep-2007 |
| Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
|
(Nektar Therapeutics)
|
10-Sep-2007 |
| Bayer Healthcare and Nektar Therapeutics to Develop Innovative Therapy for Pneumonia
|
(Bayer AG)
|
06-Aug-2007 |
| Mircera Approved in European Union for Treatment of Anaemia Related to Chronic Kidney Disease
|
(Roche)
|
26-Jul-2007 |
| Anti-Tumor Activity and Pharmacokinetic Properties of NKTR-102 (PEG-irinotecan) to be Presented at Upcoming Oncology Meeting
|
(Nektar Therapeutics)
|
26-Jul-2007 |
| First Peer-Reviewed Preclinical and Early Phase 1 Results for NKTR-118 (oral PEG-naloxol) to be Presented at Upcoming Pharmacology and Pain Management Meetings
|
(Nektar Therapeutics)
|
26-Jul-2007 |
| Once-Monthly Mircera Keeps Haemoglobin Stable in High-Risk Kidney Disease Patients with Diabetes or Heart Disease
|
(Roche)
|
25-Jun-2007 |
| PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected with HIV
|
(Schering-Plough)
|
25-Jun-2007 |
| Exubera Demonstrated Pulmonary Safety with Blood Sugar Control in Three-Year Interim Analyses
|
(Pfizer)
|
23-Jun-2007 |
